1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Verastem RAMPS Up In Rare Ovarian Cancer With Avutometinib/Defactinib Filing

Data Announced In Pancreatic Cancer

 
• By Alaric DeArment

The company announced topline data from the RAMP 201 trial in low-grade serous ovarian cancer, a rare disease with no FDA-approved treatments, and started a rolling FDA submission.

• Source: Shutterstock

Verastem, Inc. is plowing ahead with its combination of the RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib in solid tumors, announcing topline data and the start of a rolling regulatory submission for the two drugs in a rare form of ovarian cancer and interim data for the combination in pancreatic cancer.

The company held a call with analysts 24 May to discuss the recent data from the Phase II RAMP 201 study of avutometinib/defactinib in KRAS-mutant and KRAS-wild-type low-grade serous ovarian cancer (LGSOC) and its initiation of a rolling submission for accelerated approval with the US Food and Drug Administration in the KRAS-mutant population

Key Takeaways

  • Verastem announced topline data from the RAMP 201 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

  • It also initiated a rolling submission to the US Food and Drug Administration for accelerated approval, in a disease with no approved drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.